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Abstract
Huanglian-Jie-Du-Tang (HLJDT) is a famous traditional Chinese herbal formula that has been widely used clinically to treat
cerebral ischemia. Recently, we found that berberine, a major alkaloid compound in HLJDT, reduced amyloid-b (Ab)
accumulation in an Alzheimer’s disease (AD) mouse model. In this study, we compared the effects of HLJDT, four single
component herbs of HLJDT (Rhizoma coptidis (RC), Radix scutellariae (RS), Cortex phellodendri (CP) and Fructus gardenia
(FG)) and the modified formula of HLJDT (HLJDT-M, which is free of RS) on the regulatory processing of amyloid-b precursor
protein (APP) in an in vitro model of AD. Here we show that treatment with HLJDT-M and its components RC, CP, and the
main compound berberine on N2a mouse neuroblastoma cells stably expressing human APP with the Swedish mutation
(N2a-SwedAPP) significantly decreased the levels of full-length APP, phosphorylated APP at threonine 668, C-terminal
fragments of APP, soluble APP (sAPP)-a and sAPPb-Swedish and reduced the generation of Ab peptide in the cell lysates of
N2a-SwedAPP. HLJDT-M showed more significant APP- and Ab- reducing effects than berberine, RC or CP treatment alone.
In contrast, HLJDT, its component RS and the main active compound of RS, baicalein, strongly increased the levels of all the
metabolic products of APP in the cell lysates. The extract from FG, however, did not influence APP modulation. Interestingly,
regular treatment of TgCRND8 APP transgenic mice with baicalein exacerbated the amyloid plaque burden, APP
metabolism and Ab production. Taken together, these data provide convincing evidence that HLJDT and baicalein
treatment can increase the amyloidogenic metabolism of APP which is at least partly responsible for the baicalein-mediated
Ab plaque increase in the brains of TgCRND8 mice. On the other hand, HLJDT-M significantly decreased all the APP
metabolic products including Ab. Further study of HLJDT-M for therapeutic use in treating AD is warranted.
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Introduction
Extracellular senile plaques and phosphorylated tau-associated
intraneuronal neurofibrillary tangles (NFTs) are the two classical
microscopic pathologies of Alzheimer’s disease (AD) [1]. Senile
plaques comprise a dense core of amyloid-b (Ab) that is
surrounded by dystrophic neurites [1]. Ab is a 39–43 amino acid
proteolytic product of a much larger amyloid precursor protein
(APP). APP is an integral membrane protein processed by the
proteases a-secretase or b-secretase to produce a-C terminal
fragment (CTF-a) or b-C terminal fragment (CTF-b), respectively.
These fragments are subsequently cleaved by c-secretase to
produce P3 or Ab respectively, and a cytoplasmic tail dubbed
APP-intracellular domain (AICD) [1]. APP proteolysis also
releases soluble forms of APP (sAPPa and sAPPb), and these
soluble APPs may also now be considered biomarkers for AD [2].
On the other hand, monomeric Ab (4.3 kDa molecular weight)
self-assembles into oligomers. These oligomers eventually deposit
as large fibrils in extracellular space, which assemble as amyloid
plaques [1,3]. Although the precise mechanisms by which Ab may
induce neurotoxicity are still unknown, several are proposed,
including calcium influx, generation of reactive oxygen species
(ROS), nitric oxide (NO) production and increased phosphoryla-
tion of tau [4].
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The US Food and Drug Administration has approved five drugs
(i.e., tacrine, donepezil, rivastigmine, galantamine and memantine)
for the treatment of AD, but they produce only mild, symptomatic
relief and do not halt progression of dementia [5]. Therefore there
is a need for alternative drugs for the treatment of AD. One
potential source of phytotherapeutic agents is Huang-Lian-Jie-Du-
Tang (HLJDT), a traditional Chinese medicine (TCM) achieving
popularity for its therapeutic application.
Huang-Lian-Jie-Du-Tang (HLJDT) is a famous TCM formula
widely used in treating stroke and dementia. It is composed of four
herbs, namely: Rhizoma coptidis (RC) (Coptis chinensis Franch, or
Huang Lian in Chinese), Radix scutellariae (RS) (Scutellaria
baicalensis Georgi, or Huang Qin in Chinese), Cortex phellodendri
(CP) (Phellodendron amurense, or Huang Bai in Chinese) and Fructus
gardeniae (FG) (Gardenia jasminoides Ellis, or Zhi Zi in Chinese), in a
3:2:2:3 dry weight ratio. As stated in the traditional Chinese
medicinal book Wai-Tai-Mi-Yao, RC, RS, and CP are major
ingredients of HLJDT, and FG functions as an adjuvant
constituent to support the effect of the principal ingredients.
HLJDT has been used to treat senile dementia, inflammation,
digestive system upsets, and cerebrovascular disease in China [6].
HLJDT has been used to treat various clinical symptoms linked
with stroke [7] and with vascular dementia [8] in Japan. In a
Japanese clinical study, the addition of HLJDT to yokukan-san
(Japanese traditional herbal medicine) exerted the same efficacy as
aripiprazole (antipsychotics) in controlling aggressiveness in an
Alzheimer’s type dementia patient without any adverse effects [9].
Preclinical reports provide evidence that HLJDT can improve
cerebral blood flow; it potently inhibits lipid peroxidation in the
brain and thus preserves energy metabolism in the brain
[10,11,12]. Both ethanolic extracts and aqueous extracts of
HLJDT can ameliorate the cognitive impairments induced by
cerebral ischemia and central cholinergic dysfunction in animal
models [13,14]. We have recently shown that berberine, a
compound in HLJDT, can significantly reduce the Ab load in a
transgenic Alzheimer’s disease model by regulating APP process-
ing [15]. However, the exact mechanism underlying HLJDT-
mediated cognitive improvements is not known. In the context of
AD, there is a study of HLJDT in AD mice [16]. Qiu et al. [16]
reported that HLJDT reduced Ab plaques and improved memory
in APP/PS-1 mice, but the authors did not mention the
quantification of Ab load. Qiu et al. [16] also reported that
HLJDT reduced APP mRNA level but did not measure the effect
of HLJDT on the protein level of full length (Fl)-APP, Ab and
soluble forms of APP, namely, sAPPa and sAPPb. In contrast with
Qiu et al. [16], we found that HLJDT increased Fl-APP, sAPPa,
sAPPb and intracellular Ab in N2a mouse neuroblastoma cells
expressing APP with the Swedish mutation (N2a-SwedAPP cells).
We also found that RS enhances Ab generation by increasing the
protein level of APP. To further prove this we compared the effect
of HLJDT with and without RS (modified HLJDT, or HLJDT-M)
on APP processing and Ab load in N2a-SwedAPP cells. We
meticulously evaluated the effect of each individual herb of
HJLDT on the levels of APP, sAPPa and sAPPb in order to
determine which herb is responsible for increasing APP and Ab.
Materials and Methods
Chemicals and Reagents
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine
serum (FBS), penicillin, streptomycin and G418 for cell culture
were bought from Invitrogen (Carlsbad, CA, USA). Polyvinylidene
Fluoride (PVDF) membrane was obtained from Hybond-P, GE
Healthcare BioSciences (Piscataway, NJ, USA). Enhanced chemi-
luminescence (ECL) reagent was purchased from Thermo
Scientific (Rockford, IL, USA). Tetramethylbenzidine (TMB)
was purchased from BD Biosciences (Sparks, MD, USA), while
analytical grade reagents (including ethanol and methanol) were
from Sigma–Aldrich (St. Louis, MO, USA) unless otherwise
indicated. Berberine, baicalin and baicalein were purchased from
Sigma-Aldrich. Palmatine and geniposide were purchased from
Aktin Chemicals (Chengdu, China).
Monoclonal b-actin antibody was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Rabbit polyclonal CT15
antibody against the C-terminus of APP was a gift from Prof.
Edward Koo (University of California, San Diego, La Jolla, CA,
USA). Amino-terminus anti-Ab1–17 monoclonal antibody (6E10)
and a biotinylated Ab17–24 (4G8) monoclonal antibody wer-
eordered from Covance (Princeton, NJ, USA). Human anti-sAPPb
Swedish (sAPPb-sw) monoclonal antibody (clone 6A1) was
provided by IBL (Japan). Anti-pAPPThr668 polyclonal antibody
was from Cell Signaling (Danvers, MA, USA). Carboxy-terminus
biotinylated anti-amyloid bG4(1–40)-5C3 (specific to a peptide
corresponding to Ab40) and bA4(1–42)-8G7 (specific to a peptide
corresponding to Ab42) antibodies were purchased from Nano-
tools (Teningen, Germany). The streptavidin-conjugated horse-
radish peroxidase (HRP) was purchased from DAKO (Carpin-
teria, CA, USA). Ab40 and Ab42 peptides were provided by
Invitrogen (Carlsbad, CA, USA) and California Peptide (Napa,
CA, USA), respectively.
Plant Extraction
RC, RS, CP and FG were purchased from the Hong Kong
Baptist University Mr. & Mrs. Chan Hon Yin Chinese Medicine
Specialty Clinic and Good Clinical Practice Centre and from a
local Chinese medicine pharmacy. All herbs were identified and
authenticated by Prof. Zhong-Zhen Zhao from the School of
Chinese Medicine, Hong Kong Baptist University, Hong Kong.
Dry materials of the plants were ground into powder. Approxi-
mately 10 g of powder of each herb, and of the HLJDT mixture
with and without RS, were soaked in 100 mL of 80% ethanol for
1 h, with sonication at a frequency of 120 kHz (SANHO
Ultrasonic Engineering Ltd., Hong Kong); then extracted
solutions were filtered. This procedure was repeated three times.
Thus we employed this solvent to standardize the extraction and to
focus on screening. Approximately 300 mL of each extracted
solution was collected and, then concentrated by rotary evapora-
tion (EYELA, Tokyo Rikakikai Co., Ltd., Japan) under vacuum in
a 60uC water bath. All the extracts were finally subjected to
lyophilization (LABCONCO, Laboratory Construction Company,
MO, USA) at 240uC under vacuum of 105 mbar. Each yield of
plants was powdered and mixed until uniform, and then stored at
4uC for later use. Dimethyl sulfoxide (DMSO) was used as the
solvent to dissolve the extract, and it was loaded as the vehicle
control for all cell cultures. Although the aqueous extract of
HLJDT have been used in some studies, we found that the ethanol
extract was ideal to isolate most of the bioactive compounds with
higher quantity from HLJDT when compared to aqueous extract
(data not shown). It was reported that ethanol can extract higher
concentrations of flavonoid, polyphenols and more alkaloid
compounds as compared to aqueous extract [17,18]. Thus we
employed this solvent to standardize the extraction and to focus on
screening.
Chromatographic Conditions
HPLC was carried out on an Agilent 1100 series with a G1315A
diode array detector (California, USA). An AlltimaTM C18 column
(25064.60 mm, particle size 5 mm) was used for separations.
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HPLC conditions were as follows: eluent A, 0.1% formic acid in
H2O; eluent B, methanol with a linear gradient elution (0 min,
15% B; 0,15 min, 15%R38% B; 15,30 min, 38%R90% B;
30,30.1 min, 90%R100% B; 30.1,33 min, 100% B;
33,33.1 min, 100%R15% B; 33.1,36 min, 15% B) at a flow
of 1 mL/min. Peaks were assigned by matching their retention
times with that of each reference compound eluted in parallel with
the same mobile phase. The concentrations of the analytes were
determined from representative calibration curves. From the
HPLC profiles of ethanolic extract of HLJDT and its individual
herbs, we have found that, in comparing the concentrations of six
known components (geniposide, berberine, palmatine, baicalein,
baicalin and wogonin) that can be found in ethanolic extract,
berberine is most abundant (6.02%), followed by geniposide
(4.01%), baicalin (2.67%), baicalein (1.31%), palmatine (0.867%)
and wogonin (0.615%) (Figure 1B; Table S1). Based on the four
herbal components of HLJDT, we know that geniposide is
contributed by FG; berberine and palmatine are mainly found in
RC and CP, respectively; and baicalin, baicalein and wogonin are
contributed by RS. Recent studies have shown that berberine,
baicalein and geniposide have neuroprotective effects in Alzhei-
mer’s disease models [15,19,20]. Therefore, these three com-
pounds (Figure 1A) were used for quantitative analysis of ethanolic
extract of HLJDT.
Qualitative identification of 12 active compounds of HLJDT
was also performed by ultra-high performance liquid chromatog-
raphy with quadrupole time-of-flight mass spectrometry (UHPLC-
Q-TOF-MS) analysis with positive mode ESI-MS (supplementary
method). A database was prepared for the identification of
phytoconstituents of HLJDT based upon their molecular masses,
calculated m/z values and retention times (Rt) observed in the
analysis (Table S1). Representative LC-MS base peak chromato-
grams (BPC) and extracted ion chromatograms (EIC) are shown in
Figure S1. By matching the Rt and m/z values between samples
and reference standard solutions (Table S2), eight characteristic
peaks of HLJDT were identified in HLJDT sample solutions as
geniposide, coptisine, jatrorrhizine, baicalin, palmatine, berberine,
baicalein, wogonin, phellodendrine, columbamine, epiberberine
and wogonoside were identified based on published articles related
to the profiling of chemical components of HLJDT [21,22].
Cell Culture
N2a-SwedAPP cells [23] were obtained from Dr. Gopal
Thinakaran (University of Chicago, Chicago, IL, USA). N2a-
SwedAPP cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) and OPTI-MEM medium in a 1:1 ratio with
5% FBS, 50 mg/mL penicillin, 50 mg/mL streptomycin and
200 mg/mL G418 as previously described [23]. N2a-SwedAPP
cells were incubated at 37uC in a 5% CO2/95% humidity
Figure 1. Selected components of Huang-Liang-Jie-Du-Tang (HLJDT). A. Chemical structures of main compounds of Huang-Liang-Jie-Du-
Tang (HLJDT). B. Quality analysis of HLJDT (at 245 nm) (A); Fructus gardeniae (FG) (at 245 nm) (B); Rhizoma coptidis (FG) (at 275 nm) (C); Radix
scutellariae (RS) (at 275 nm) (D); Cortex phellodendri (CP) (at 275 nm) (E). Peaks of these compounds are shown: 1. Geniposide; 2. Berberine; 3.
Palmatine; 4. Baicalein; 5. Baicalin; 6. Wogonin.
doi:10.1371/journal.pone.0092954.g001
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incubator. Cells were seeded 24 h prior to the treatments. When
growth reached close to 90% of confluence, cells were transferred
into DMEM with 1% FBS for loading extracts. The final
concentration of DMSO in all experiments was 0.1%, and this
concentration caused no cytotoxicity.
Viability Assay
For the viability assay, N2a-SwedAPP cells were seeded in a 96-
well plate (7000 cells/well and 5000 cells/well) for 48 h. The
exhausted medium was replaced after 24 h with 200 mL DMEM
with 1% FBS and various concentrations (0, 3.125, 6.25, 12.5, 25
or 50 mg/mL) of each extract or various concentrations (0, 3.125,
6.25, 12.5 or 25 mM) of berberine, baicalein or geniposide, and
cells were incubated at 37uC in 5% CO2 for 48 h. Then the media
were removed and 100 mL of phenol red-free DMEM containing
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) was added to each well to a final concentration of
0.5 mg/mL and further incubated for 4 h. The MTT-containing
medium was removed, and the cell crystals were dissolved using
100 mL of 20% sodium dodecyl sulfate (SDS) in 50% N, N-
dimethylformamide. Finally, optical intensity was measured using
a BioRad plate reader at 570 nm and a reference of 620 nm.
Experiments were conducted independently three times.
Detection of Intracellular APP and Soluble APPs in N2a-
SwedAPP Cells
To detect the levels of APP metabolic products, the cell lysates
and the conditioned media were prepared as described previously
by Durairajan et al. [24], with minor modification. N2a-SwedAPP
cells were seeded at a density of 46105/mL in DMEM medium in
a 6-well plate and cultured for 1 day. After transfer, cells were
treated with different doses of RC, CP, FG and RS for 48 h, then
the extracellular media were collected for detection of sAPPa and
sAPPb-sw, and cells were harvested to quantify Fl-APP and b-
actin by Western blot analysis, as described previously [24]. For
intracellular APP, APP-CTFs and Ab preparation, cells were
washed with ice-cold PBS twice and solubilized in ice-cold RIPA
buffer with protease inhibitor cocktail added. Lysates were
collected and centrifuged at 16,0006g for 15 min at 4uC. The
resulting supernatants were collected, and their protein concen-
trations were determined with bicinchoninic acid (BCA) protein
assay reagent (Thermo Scientific, IL, USA). For sAPPa and
sAPPb-sw detection, the conditioned media were collected and
frozen in liquid nitrogen, subjected to lyophilization at 240uC
under vacuum of 105 mbar for 2 days in order to remove all liquid.
The conditioned media were standardized to total cell lysate
protein.
Animals and Baicalein Treatment
All animal handling experiments were approved by the Hong
Kong Baptist University Committee on the Use of Human and
Animal Subjects in Teaching and Research (HASC, approval #:
12–13/0030). TgCRND8 mice expressing human APP with
Swedish (K670N/M671L) and Indiana (V717F) mutations were
used to evaluate the effect of baicalein on Ab. Heterozygous
TgCRND8 mice on a C57BL/6J background [25] were used to
breed a colony of experimental animals. The TgCRND8 mouse is
an early onset model of AD with visible Ab deposits in the brains
of the animals starting from 3 months of age [25]. The animals
were housed in a controlled environment under a 12/12 h light/
dark cycle. They were allowed free access to food and water. The
oral administration of baicalein (25 mg/kg/d) was commenced at
2 months of age and ended at 5 months before being killed. We
tested a single dose (25 mg/kg/d) of baicalein in our animal study
because in our pilot study we did not find any difference in the
brain levels of baicalein between doses of 25 and 50 mg/kg/d
(data not shown). Control mice were orally gavaged with tap water
only for the same administration period. At the conclusion of the
treatment period, mice were deeply anesthetized by chloral
hydrate and perfused with phosphate buffered saline (PBS). The
brains were then dissected and processed for Ab immunostaining.
Serial Differential Fractionation with Ultracentrifugation
To detect differences in the level of APP metabolic products
among treatment groups, the levels of Ab, Fl-APP, pAPPThr668,
CTFs, sAPPa and sAPPb-sw were measured after a 3-step
sequential extraction using Tris buffered saline (TBS) (pH 7.4),
1% Triton X-100/TBS (TBSX) and formic acid (FA) methods as
described elsewhere [26]. All extraction buffers also contained
protease and phosphatase inhibitor cocktail (Roche Diagnostics,
Basel, Switzerland). Snap frozen tissue was homogenized in 15
volumes (w/v) of TBS homogenization buffer and centrifuged at
100,0006g for 1 h at 4uC using a Type 70 Ti rotor in an
OptimaTM L-80XP Ultracentrifuge (Beckman Coulter, FL, USA).
The TBS-soluble fraction was aliquoted, frozen in liquid nitrogen
and stored at 280uC. The pellets were resuspended in 15 volumes
of TBSX and kept on ice for 30 min, followed by a second
centrifugation at 100,0006g for 1 h at 4uC. The TBSX soluble
fraction was aliquoted, frozen and stored as for the TBS fraction.
The TBSX-insoluble pellet was resuspended in 2 mL of 70% FA
and centrifuged at 100,0006g at 4uC for 1 h. The FA extracts
were neutralized by the addition of 20 volumes of 1 M Tris
pH 11, aliquoted and stored at 280uC. Total protein content in
TBS- and TBSX-extracts was determined via BCA assay. Total
protein in FA-extracts was determined by Bradford Protein
Microassay (Bio-Rad, CA, USA).
Ab Measurements
The levels of intracellular Ab1–40 and Ab1–42 were quantified
by using a sandwich ELISA as previously described by Durairajan
et al. [15,24], with minor modification. Equal amounts of cell or
brain lysates were used for Ab quantification by sandwich ELISA.
The monoclonal antibody 6E10 was used as the capture antibody
by adding to ELISA plates (0.2 mg diluted in 0.1 M Na2CO3
(pH 9.6) per well) and incubated overnight at 4uC. The plates
were washed with PBS (0.05% Tween 20) and blocked with 4%
BlockAce (Serotec, Raleigh, NC, USA) for 2 h at room
temperature. Equilibrated protein lysates from each treatment (a
100 mL volume was adjusted in all treatment groups by using PBS)
were applied in duplicate and incubated at room temperature for
2 h with constant rotation at 30 rpm. Biotinylated monoclonal
anti-Ab40 5C3 (50 ng per well) and biotinylated monoclonal 8G7
(50 ng per well) antibodies were used for detection of Ab1–40 and
Ab1–42, respectively, and were diluted in 1% BlockAce and
incubated for 2 h at room temperature. Plates were thoroughly
washed with PBS (0.05% Tween 20), and streptavidin conjugated
HRP was added for 1 h at room temperature. Finally the plates
were washed four times with PBST before adding the substrate
TMB for 30 min. Absorbance at 450 nm was measured in
duplicate wells after addition of 2 M H2SO4. All ELISA
experimental data were from three different days. Synthetic
Ab40 and Ab42 peptides were used for construction of calibration
curves, and Ab was measured in lysates.
SDS-PAGE and Western Blot Analysis
For Western blot analysis from cell culture or mouse brain, 10–
30 mg total protein was separated on 10% and 15% SDS–PAGE
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gels and blotted onto PVDF membranes for the detection of full
length APP (Fl-APP), CTFs, sAPPa, sAPPb-sw, b-actin and
phosphorylated APP (pAPPThr668). After blocking with 5% skim
milk, the blots were incubated with primary antibodies overnight
at 4uC with shaking. Blots were washed and incubated with HRP-
conjugated secondary antibodies. The goat anti-mouse IgG was
used when the primary antibody was 6E10 (1:1000), sAPPb-sw
(1:100), or anti-b-actin (1:5000), and the goat anti-rabbit IgG was
used when the primary antibody was anti-CT15 (1:5000) or
pAPPThr668 (1:1000). After incubation with HRP-conjugated
secondary antibody, immunoblots were treated with ECL and
developed using X-ray films (Fujifilm). Films were scanned, and
the band intensity was analyzed using Image J software (NIH
Image).
Membranes probed with primary antibodies CT15 and 6E10
was stripped using stripping buffer (62.5 mM Tris–HCl pH 7.6,
100 mM 2-mercaptoethanol and 2% SDS) at 60uC for 20 min,
then washed with a generous amount of TBST for 20 mins twice
and finally blocked with 5% milk for 1 h. Stripped CT15 and
6E10 probed membranes were reincubated with pAPPThr668
and sAPPb-sw 6A1 antibodies, respectively.
Immunohistochemistry
Immunohistochemistry and image analysis of Ab plaques was
performed on coronal brain sections from TgCRND8 mice
treated with baicalein or tap water as described previously by
Durairajan et al. [15]. For immunohistochemical analysis, 30 mm
thick sections were obtained using a Thermo Shandon CryotomeH
(Thermo Sceintific) slicing system. The free-floating sections were
quenched for the endogenous peroxidase activity, and the sections
were incubated overnight at 4uC with a biotinylated4G8 antibody
(1:1000);. After removing excess primary antibody, sections were
washed 3 times, and immunostaining was performed using a
Vectastain ABC Elite kit (Vector Laboratories, Burlingame, CA,
USA) linked with the diaminobenzidine reaction. Images were
obtained with a Nikon fluorescent inverted microscope with digital
Nikon camera and analyzed by Image J software. Ab plaque
burden was calculated as the area occupied by the Ab plaques as a
percentage of total area of the brain sections.
Statistical Analysis
The results are displayed as mean 6 standard error (SE), with
n=3 or 5 per group for all comparisons. Statistical analysis was
performed by one-way analysis of variance (ANOVA) followed by
Fisher’s Least Significant Difference (LSD) for in vitro experiments.
In animal experiments, the student T test was performed.




N2a-SwedishAPP cells are widely used as a cellular model of
Alzheimer’s disease, because they express a high level of APP and
Ab [23]. The effects of HLJDT and its components on viability of
N2SwedAPP cells were monitored by using the MTT assay. We
ascertained each extract and compound of HLJDT components
for cytotoxicity for at least 48 h at five different concentrations; we
considered the non-toxic concentration as the highest concentra-
tion that showed more than 90% cell viability (Figure 2). The
DMSO concentration is 0.1% throughout the experiments and
there is no cytotoxicity at this concentration. The non-toxic
concentrations of RC (50 mg/mL), CP (25 mg/mL), FG (50 mg/
mL), RS (1.56 mg/mL), HLJDT (12.5 mg/mL) HLJDT-M (25 mg/
mL), berberine (12.5 mM) and baicalein (12.5 mM) were used to
investigate the APP modulating effects on N2SwedAPP cells for
48 h. According to the contents of pure compounds in each herbal
component of HLJDT (Table S1), there is a correlation between
the effective concentration of berberine in RC (11 mM of
berberine in 25 mg/mL of RC) and berberine (12.5 mM) alone,
however, there is no exact correspondence between the highest
effective concentration of baicalien in RS (0.1 mM of baicalein in
1.56 mg/mL of RS) and baicaein (12.5 mM) alone. The non-toxic
concentrations of HLJDT components were used in the following
experiments.
Modulation of APP Processing by RC, RS, CP, and FG and
S
We used Western blotting of N2a-SwedAPP cells to test for
differences in the processing of Swedish mutant APP by HLJDT
components. We used several antibodies in Western blot analysis:
CT15 recognizes full length APP (Fl-APP), 6E10 identifies only a-
secretase-cleaved APP i.e sAPPa, and the sAPPb-sw specific for b-
secretase cleavage of Swedish mutant APP. Several studies suggest
that APP phosphorylation affects the maturation and subcellular
distribution of APP, increases production of CTFs, and stimulates
generation of Ab [26,27], therefore we examined APP phosphor-
ylated at threonine 668 using an antibody to pAPPThr688.
As shown in Figure 3, the levels of Fl-APP, pAPPThr688 and
soluble APPs (sAPPa and sAPPb-sw) were decreased by treatment
with RC or CP in a concentration-dependent manner (Figure 3A
and 3B). A low concentration of RC or CP (12.5 mg/mL) reduced
the Fl-APP level by 42% or 38%, respectively. At 25 mg/mL, Fl-
APP was reduced by 55% or 71% by RC or CP, respectively.
Treatment with RC or CP decreased the level of phosphorylated
APP. At 25 mg/mL, pAPPThr668 was reduced by 39.5% or
40.5% by RC or CP, respectively. Thus, RC or CP reduced the
levels of Fl-APP and pAPPThr668. There was also a clear decrease
in the levels of sAPPa and sAPPb-sw. The level of sAPPa was
reduced by 71% (p,0.001) or 83% (p,0.01) by treatment with
RC or CP, respectively, at a concentration of 25 mg/mL. Similarly
the level of sAPPb-sw dropped significantly upon treatment with
25 mg/mL (p,0.01) of RC or CP, but 12.5 mg/mL of RC had no
significant effect (p.0.05).
However, FG did not influence the level of Fl-APP, nor did it
affect pAPPThr668 metabolism; the only significant effect of FG
was a slight decrease in sAPPa at a concentration of 50 mg/mL
(Figure 3C). In contrast with RC, CP and FG, RS significantly
increased soluble APPs, intracellular APP and pAPPThr668 in a
dose-dependent manner (Figure 3D). The level of maximal
stimulation of Fl-APP and pAPPThr668 by RS is 1.89- and 2-
fold of basal release, respectively, at a concentration of 1.56 mg/
mL. The release of sAPPs was accelerated by treatment with RS in
a dose dependent manner, reaching maximal augmentation at 1.4-
and 2.4- fold of basal release for sAPPb-sw and sAPPa,
respectively, at a concentration of 1.56 mg/mL. These results
demonstrate that the herbal components of HLJDT show
differential modulation of APP processing.
Modulation of APP Processing by HLJDT and HLJDT-M
Though RS increased APP metabolism, we still sought to test
the effect of HLJDT on APP metabolism in N2aSwedAPP cells
because we speculated that the other herbal components in the
formula might lead to a net reduction in APP metabolism. In
contrast to our expectation, HLJDT significantly increased soluble
APPs, intracellular APP, pAPPThr668 and CTFs in a dose-
dependent manner (Figure 4A). The level of maximal increase of
Fl-APP and pAPPThr668 by HLJDT was 2.0- and 2.8- fold of
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basal release, respectively, at a concentration of 12.5 mg/mL.
HLJDT treatment not only increased the level of Fl-APP and
pAPPThr668 but also dose-dependently increased the generation
of CTFs, confirming the APP-increasing effect of HLJDT. HLJDT
increased CTFs to 2.1 or 2.3 times the basal levels at
concentrations of 12.5 (p,0.05) or 6.25 (p,0.05) mg/mL,
respectively. Accordingly, sAPPa and sAPPb-sw were also
elevated. The release of sAPPs was accelerated by treatment with
HLJDT in a dose-dependent manner, reaching maximal aug-
mentation at 1.4 and 2.4 fold of basal release for sAPPb-sw and
sAPPa, respectively, at a concentration of 3.125 mg/mL. The
increase in sAPPs levels is consistent with the increase in Fl-APP
and CTFs levels by HLJDT, and indicates that HLJDT increases
amyloidogenic processing of APP.
Since both RS and HLJDT increased APP metabolism, we
modified the HLJDT formula (HLJDT-M) by removing RS; RC,
CP and FG were included in HLJDT-M at a ratio of 4:24,
respectively. As expected, HLJDT-M significantly and dose-
dependently decreased all metabolic products of APP to an even
greater extent than RC and CP alone. HLJDT-M treatment at a
concentration of 12.5 mg/mL reduced the levels of Fl-APP,
pAPPThr668 and CTFs by 79% (p,0.01), 60% (p,0.001) and
68% (p,0.001), respectively (Figure 4B). The levels of sAPPa and
sAPPb-sw were reduced by 70% (p,0.001) and 57% (p,0.01),
respectively (Figure 4B). The removal of RS from HLJDT totally
reversed the amyloidogenic property of HLJDT.
Modulation of APP Processing by Berberine and Baicalein
Berberine and baicalein have been extensively studied as
markers for HLJDT, therefore the effects of these pure compo-
nents of HLJDT on APP metabolism were examined. We had
already determined that berberine significantly decreases Ab,
pAPPThr688 and CTFs in both in vivo and in vitro models of AD
[15]. However, we had not studied the effect of berberine on the
level of soluble APPs; therefore we proceeded to assess the effect of
berberine on APP metabolism in N2a-SwedAPP cells. As
expected, berberine significantly decreased soluble APPs, intracel-
lular APP, pAPPThr668 and CTFs in a dose-dependent manner
(Figure 5A). Levels of sAPPa and sAPPb-sw were reduced by 58%
(p,0.01) and 70% (p,0.001), respectively, by treatment with
12.5 mM berberine, and by 30% (p,0.05) and 45% (p,0.01) by
6.25 mM berberine. Berberine treatment at a concentration of
12.5 mM reduced the level of Fl-APP, pAPPThr668 and CTFs by
54% (p,0.01), 42% (p,0.05) and 67% (p,0.01), respectively.
Since RS and HLJDT increased all APP metabolic products, we
ascertained whether baicalein alone can induce the same APP
increasing effect as did RS and HLJDT. As hypothesized,
baicalein significantly increased soluble APPs, Fl-APP,
pAPPThr668 and CTFs in a dose-dependent manner
(Figure 5B). The levels of maximal increase of Fl-APP,
pAPPThr668 and CTFs by baicalein were 1.68 (p,0.05), 1.58
(p,0.01) and 2.36 (p,0.05) fold of basal release, respectively, at a
concentration of 12.5 mM. The release of sAPPs was accelerated
by treatment with baicalein in a dose-dependent manner, reaching
Figure 2. Effects of HLJDT, HLJDT-M, constituent herbs and constituent compounds on toxicity in N2a-SwedAPP cells. N2a-SwedAPP
cells were treated with the ethanolic extracts of (A) RC, CP, FG, or (B) RS; (C) HLJDT or HLJDT-M; or (D) berberine or baicalein. Cell viability was
determined by MTT assay. The values denote the results of three different experiments and are shown as mean6S.E.M. P values are for comparison
with control: *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0092954.g002
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maximal secretion of 2.65 (p,0.01) and 1.70 (p,0.05) fold of
basal release for sAPPa and sAPPb-sw, respectively, at a
concentration of 12.5 mM. These data suggest that berberine is
one of the alkaloids responsible for the APP-decreasing effect of
HLJDT-M, and baiclein is one of the flavonoids responsible for
the APP-increasing effect of HLJDT.
Modulation of Intracellular Ab Levels by HLJDT, HLJDT-M
and its Components in N2a-SwedAPP Cells
Since HLJDT and its components modulated intracellular levels
of APP and CTFs in N2a-SwedAPP, we investigated the effect of
HLJDT and its components on the level of intracellular Ab, which
is a key factor in AD progression [29]. We treated N2a-SwedAPP
cells with different non-toxic concentrations of HLJDT, HLJDT-
M and its components and then analyzed intracellular Ab levels by
ELISA (Figure 6). There was a dose-dependent reduction in both
Ab1–40 and Ab1–42 by both RC and CP treatments. Intracellular
Ab1–40 markedly dropped 41% and 29% due to treatment by
25 mg/mL RC and CP, respectively (Figure 6A). There was a 32%
reduction in intracellular Ab1–42 in both RC and CP treated cells
at the same high concentration. In contrast, RS treatment
increased intracellular Abs in a dose-dependent manner, reaching
maximal accumulation of 1.4- and 1.6- fold of basal levels of Ab1–
40 and Ab1–42, respectively, at a concentration of 1.56 mg/mL
(Figure 6B).
When comparing the effects of HLJDT and HLJDT-M on the
level of intracellular Abs, as expected, HLJDT increased both
Ab1–40 and Ab1–42 in a dose-dependent manner, reaching
maximal accumulation of 1.4- and 1.6- fold of basal level,
respectively, at a concentration of 12 mg/mL (Figure 6C). By
contrast, HLJDT-M decreased both Ab1–40 and Ab1–42 in a
dose-dependent manner. Intracellular Ab1–40 markedly dropped
44% with 12.5 mg/mL of HLJDT-M, 38% with 6.25 mg/mL and
20% with 3.12 mg/mL. Ab1–42 was reduced 48% by 12.5 mg/mL
of HLJDT-M, 39% with 6.25 mg/mL and 33% with 3.12 mg/mL
(Figure 6C). These data suggest that HLJDT-M, which lacks RS,
significantly reduced intracellular Abs, and that the Ab-reducing
effect is far better than that of the individual herbal components of
HLJDT-M. We also confirmed the above outcome by using two
pure HLJDT components (berberine and baicalein). At a
concentration of 12.5 mM, berberine significantly reduced both
Ab1–40 and Ab1–42 by 37% and 25%, respectively, whereas
baicalein significantly augmented both Ab1–40 and Ab1–42 to
1.23 and 1.38 fold of basal level (Figure 6D). These findings
provide evidence regarding the effects of HLJDT, HLJDT-M and
its components on APP metabolism and Ab levels.
Figure 3. Extracts of HLJDT constituent herbs alter the processing of APP in N2a-SwedAPP cells. Conditioned medium and cell lysates
were prepared from N2a-SwedAPP cells that were treated with (A) RC, (B) CP, (C) FG or (D) RS at various doses as indicated for 48 h. Western blotting
was used to detect sAPPa and sAPPb-sw in conditioned medium, and to detect Fl-APP, pAPPThr668 and b-actin in cell lysates. Bars represent
mean6S.E.M. for three experiments. One-way ANOVA revealed significant differences due to treatment at various doses of components of HLJDT:
*p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0092954.g003
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Chronic Baicalein Administration Increases Ab Plaque
Burden, Ab Levels and Amyloidogenic APP Processing in
TgCRND8 Mice
Since cell models of AD may not represent the in vivo efficacy of
herbal components, we have tested the efficacy of berberine and
baicalein, two widely studied compounds in HLJDT, in a
TgCRND8 mouse model of AD. We recently reported that
chronic administration of berberine can significantly reduce Ab
pathology, gliosis and cognitive impairments in TgCRND8 mice
via reducing the level of C-terminal fragments of APP and the level
of phosphorylated APP [15]. However the observation that
baicalein treatment increased APP metabolites and intracellular
Ab in a cell culture study directed us to examine the effect of
baicalein on Ab plaque load in TgCRND8 mice. We found that
chronic oral administration of baicalein at 25 mg/kg per day for
nearly 3 months did not significantly change animal body weight,
nor did it cause any notable adverse side effects in TgCRND8
mice (data not shown). Immunostaining of amyloid plaques in the
brains of TgCRND8 mice revealed that baicalein treatment
increased the area occupied by Ab deposits in cortex and
hippocampus by 44% (p,0.05) (Figure 7).
The above results of increased 4G8-positive Ab deposits by
baicalein treatment were further ascertained by Ab ELISA
analysis in the other hemisphere of the brain. Ab1–40 and Ab1–
42 levels in TBS, TBSX and FA brain fractions were measured via
ELISA. Baicalein treatment did not significantly affect TBS
soluble Ab levels but did significantly increase both TBSX-soluble
and insoluble formic acid fractions (Figure 8A, 8B and 8C). In the
Figure 4. Modulation of APP processing by HLJDT and HLJDT-M in N2a-SwedAPPcells. Conditioned medium and cell lysates were
prepared from N2a-SwedAPP cells that were treated with (A) HLJDT or (B) HLJDT-M at various doses as indicated for 48 h. Western blotting was used
to detect sAPPa and sAPPb-sw in conditioned medium, and to detect Fl-APP, pAPPThr668, CTFs and b-actin in cell lysates. Bars represent
mean6S.E.M. for three experiments. One-way ANOVA revealed significant differences due to treatment at various doses of HLJDT or HLJDT-M: *p,
0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0092954.g004
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TBSX-soluble fraction, the increases of Ab1–40 and 1–42 were
35% (p,0.05) and 65% (p,0.01), respectively, whereas in the FA
fraction, the corresponding increases were 80% (p,0.001) and
32% (p,0.01).
To examine the modulation of APP processing by baicalein
treatment, we subjected the serially extracted fractions to Western
blot analyses to specifically detect soluble and membrane
associated APP as described elsewhere. The TBS fraction was
analyzed for sAPPa and sAPPb-sw, and the TBSX fraction was
analyzed for Fl-APP, CTFs and pAPPThr668. Antibodies specific
for sAPPb-sw and sAPPa revealed increases in signal intensities of
35% (p,0.01) and 44% (p,0.05), respectively, after baicalein
treatment (Figure 8D). Immunoblot analysis also showed 30%,
40% and 41% increases in the levels of Fl-APP, CTFs, and pAPP,
respectively (Figure 8D). The increased metabolic products of APP
following baicalein treatment in mice is also consistent with our
interpretation of in vitro data that baicalein increases amyloido-
genic processing of APP.
Discussion
The clinical uses of HLJDT, which has been traditionally
prescribed in China to treat gastrointestinal diseases, acute liver
injury and cardiovascular diseases [30,31], have now been
extended to treat patients with cerebrovascular disease and
vascular dementia in China and Japan [6,7,8]. An improved
formula of HLJDT in a pill form has been approved by the
Chinese State Food and Drug Administration (drug approval
number Z20025356) [32]; however, the approval by the regulatory
authorities for use in AD dementia in both China and Japan is still
pending due to lack of efficacy data. Pharmacological in vitro and
in vivo studies have confirmed the neuroprotective activities of
Figure 5. Modulation of APP processing by berberine and baicalein in N2a-SwedAPP cells. Conditioned medium and cell lysates were
prepared from N2a-SwedAPP cells that were treated with (A) berberine or (B) baicalein at various doses as indicated for 48 h. Western blotting was
used to detect sAPPa and sAPPb-sw in conditioned medium, and to detect Fl-APP, pAPPThr668, CTFs and b-actin in cell lysates. Bars represent
mean6S.E.M. for three experiments. One-way ANOVA revealed significant differences due to treatment at various doses of berberine or baicalein:
*p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0092954.g005
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HLJDT against cerebrovascular diseases [10,13,14]. Three single
pure compounds (berberine, baicalein and geniposide) from
HLJDT show activities in different AD models [15,19,20]. In an
experimental plan primarily designed to identify key herbs and
compounds responsible for the neuroprotective effects of HLJDT
in an in vitro AD model, N2aSwedAPP cells, we unexpectedly
found that RS alone and HLJDT instead strongly increased Fl-
APP, pAPPThr668, CTFs, sAPPs and Ab (Figure 3D and 4A).
The increased Ab levels also translated into increased amyloid
plaque burden in a mouse model of Alzheimer’s disease (Figure 7
and 8). However, the modified HLJDT (that is HLJDT-M, which
is HLJDT without RS) significantly decreased all the APP
metabolic products including Ab (Figure 4B and 6C). HLJDT is
a formulation of RC, RS, CP and FG at the ratio of 3:2:2:3.
However, the herbal components of HLJDT-M (RC, CP, FG)
were prepared at the ratio of 4:2:4 respectively due to the following
reasons: 1) We found that RS enhances Ab load and thus reduces
the efficacy of the HLJDT formula; 2) Since RS is an anti-
oxidative herb [33,34] and its removal from HLJDT-M may
reduce the anti-oxidative capacity of HLJDT-M; and, 3) Because
FG and its pure compounds have been shown to have significant
antioxidative and memory enhancing activity without influencing
APP modulation [35,36], we have increased 3 parts FG to 4 parts;
4) Because RC is considered to be the ‘‘King drug’’ of HLJDT,
and the amounts of related protoberberine alkaloids (e.g.
palmatine) in RC are significantly higher compared to the
adjunctive drug CP (Table S1), we have increased 3 parts RC to
4 parts; and 5) In order to bring the total to 100%, the amount of
CP was unaltered, at 2 parts. Since we have recently determined
that berberine can reduce pAPPThr668, CTFs and amyloid
plaque burden in a mouse model of AD [15], we conclude that the
Ab-reducing effect of RC, CP or HLJDT-M may be mainly due to
the presence of berberine in HLJDT-M. We found that berberine
can decrease both sAPPa and sAPPb-sw, in addition to reducing
Figure 6. Regulation of the levels of intracellular Ab by HLJDT, HLJDT-M and its components in cultured N2a-SwedAPP cells. Ab1–40
and Ab1–42 peptides were analyzed by enzyme-linked immunosorbent assay (ELISA) in N2a-SwedAPP cell lysates 48 h after addition of (A) RC or CP;
(B) RS; (C) HLJDT or HLJDT-M; or (D) berberine or baicalein. Bars represent mean6S.E.M. of the level of intracellular Ab1–40 or Ab1–42 peptides in
three experiments relative to DMSO control (untreated). One-way ANOVA revealed significant differences due to treatment: *p,0.05; **p,0.01;
***p,0.001.
doi:10.1371/journal.pone.0092954.g006
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pAPPTh668 and CTFs accumulation (Figure 5A and 6D). Since
sAPPa and sAPPb-sw have recently been considered potential
markers of AD [2], the sAPPs reducing effect of berberine adds to
the evidence for its anti-AD effect. HLJDT-M shows more
significant APP- and Ab- reducing effects than berberine, RC or
CP treatment alone. The greater APP and Ab reducing effect of
HLJDT-M is most probably due to the synergistic action of related
protoberberine alkaloids (coptisine, palmatine, jatterorhizine etc.)
with berberine. Similarly, the greater APP and Ab increasing
effect of RS or HLJDT is most probably due to the synergistic
action of other flavonoids (baicalin, wogonin, wogonoside etc.)
with baicalein. The overall influence of HLJDT components on
APP metabolic products are shown in Table 1.
It has been revealed that APP phosphorylation at position
Thr668 accelerates the accumulation of CTFs and increases Ab
generation [37]. Several studies have revealed that APP matura-
tion and its targeting for proteolysis by secretases require APP
Thr668 phosphorylation [27,37]. The fast anterograde axonal
transport of pAPPThr668 to the nerve terminals, where b- and a-
secretase mediated cleavage occurs, results in increased Ab release
[27,28,37]. This indicates that berberine-mediated reduction of
APP phosphorylation might subsequently result in a reduction of
mature pAPPThr668 and a reduced level of Fl-APP engaged in
distal axons of neurons, which would prevent Ab generation at
synaptic terminals. Our study on berberine is in line with a
previous study showing that lithium and JNK inhibitor peptide (D-
JNKI1) reduce the Ab burden mainly via reducing CTFs, pAPP
Figure 7. Baicalein increased cortico-hippocampal Ab plaque pathology in TgCRND8 mice. Coronal sections of TgCRND8 mice treated
with (A) vehicle or (B) baicalein (25 mg/kg per day) and sacrificed after 3 months of treatment, followed by immunohistochemical staining for Ab
using 4G8 antibody. Digital images of cortex and hippocampus were captured and analyzed with Image J software. Scale bar: 100 mm. (C) The
percentage of coronal brain area occupied by Ab immunoreactivity. Bars represent mean6S.E.M. for five mice per group. Student’s t-test revealed a
significant difference due to treatment: *p,0.05.
doi:10.1371/journal.pone.0092954.g007
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and Fl-APP [38,39] without changing the level of BACE-1. In
particular, D-JNKI1 has also been shown to reduce both sAPPa
and b, similar to our finding that HLJTD-M, RC and their pure
compound berberine significantly reduced sAPPs.
While there are several herbal compounds that have been found
to reduce Ab generation and its aggregation
[15,20,24,40,41,42,43], baicalein is the first herbal compound
that has been shown to potentiate Alzheimer’s pathology both
in vitro and in vivo (Figure 5B, 6D, 7 and 8). Baicalein’s ability to
increase APP, pAPPThr668 and CTFs as judged by Western
analysis may partially account for the increased Ab generation
(Figure 5B, 6D, 7 and 8). A plausible mechanism by which
baicalein enhances Ab deposition is modulation of APP process-
ing, because the levels of APP-CTFs, the direct precursor of Ab
[44], were increased by baicalein treatment (Figure 5b). APP
processing can be modulated in a number of ways, such as
Figure 8. Baicalein treatment increases amyloidogenic processing in TgCRND8 mice. Serial extraction of (A) TBS-soluble, (B) TBSX-soluble
(C) and FA-soluble Ab1–40 and Ab1–42 from cerebral hemispheres of five vehicle-treated or five baicalein-treated (25 mg/kg per day) TgCRND8 mice,
measured by sandwich ELISA. Immunoblots demonstrating the levels of sAPPs, Fl-APP, pAPPThr668, CTFs and b-actin in (D) TBS- and (E) TBSX-
extracted brain lysates from the above mice. Densitometric analysis of the immunoblots, performed using Image J, with signals normalized to those
for b-actin. Bars represent mean6S.E.M. for five mice per group. Student’s t-test revealed a significant difference due to treatment: *p,0.05, **p,
0.01.
doi:10.1371/journal.pone.0092954.g008
Table 1. The overall influence of HLJDT components on APP metabolic products.
Components Fl-APP pAPP CTFs sAPPa sAPPb Abs
RC Q Q nd Q Q Q
CP Q Q nd Q Q Q
FG « « nd « « nd
RS q q nd q q q
HLJDT q q q q q q
HLJDT-M Q Q Q Q Q Q
Berberine Q Q Q Q Q Q
Baicalein q q q q q q
Qdecreased, qincreased, «unchanged, nd not determined.
doi:10.1371/journal.pone.0092954.t001
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alterations in the function of b-secretase (BACE-1) or variation in
APP transport [45,46,47,48]. We did not observe any significant
change in the levels of BACE-1 protein (data not shown), thus
baicalein may modulate APP processing through another mech-
anism. We believe that baicalein treatment augments the
abnormal processing of neuronal APP generating amyloidogenic
fragments that, upon proteolysis, form Ab. Similar to our study on
the Ab potentiating effect of baicalein, the anticancer drug
cladribine and the proton-pump inhibitor lansoprazole have
recently been shown to significantly increase the generation of
Ab and amyloid plaques in cellular and animal models of AD
[49,50]. These Western drugs also significantly and dose
dependently increased CTFs and sAPPs, in line with our findings
that baicalein, RS and HLJDT mediated increases of APP
metabolic products.
Since the completion of this manuscript, Zhang et al. [51]
reported that baicalein reduces Ab by promoting the non-
amyloidogenic pathway in Chinese hamster ovary cells expressing
wild type APP (CHO-APPwt) and in the Tg2576 mouse model of
AD. This is in strong contrast to our reports that baicalein
treatment of N2a-Swedish APP cells and of the TgCRND8 mouse
model of AD resulted in a dramatic increase of APP and Ab load.
Although Zhang et al. showed that baicalein increases the
secretion of sAPPa, they did not show corresponding increases
in the CTFa level or decreases in the sAPPb level. In fact, their
data appeared to show an increase in the level of Fl-APP in CHO-
APPwt cells although they claimed that the level of Fl-APP did not
change, yet no details were provided regarding quantification of
the level of Fl-APP. Another difference between our studies was
the duration of incubation with baicalein. We treated cells with
baicalein for 48 hours to observe the APP processing, while they
treated only 12 hours. It is usually recommended that tests for the
efficacy and toxicity of natural compounds should last 24–48 hours
[52]. In addition, Zhang et al. did not perform immunohisto-
chemistry of Tg2576 mouse brain sections to quantify the Ab
burden.
Although berberine and baicalein showed opposite effects on
Ab and are both components of HLJDT, the net effect of HLJDT
was to increase Ab load. Perhaps this is because baicalein (1–
10 mM) has greater brain bioavailability [53] than berberine
[15,54]. Only one pharmacokinetic study has reported the
concentration of baicalein (quantity not shown) in rat brain after
oral administration of HLJDT; the concentration was very low
after a dose of 20 g/kg HLJDT (equivalent to 30 mg/kg baicalein)
[55]. In our study, the mean concentration of baicalein in the
brain of TgCRND8 mice was 0.1260.01 mg/mL when orally
administered at a concentration of 25 mg/kg. In our in vitro study,
the highest Ab-increasing concentration of baicalein in HLJDT
(12.5 mg/mL) was 0.16 mg/mL, which is comparable to the
effective in vivo concentration of baicalein. These findings indicate
that baicalein may induce amyloidogenic activity in vivo. Although
HLJDT was shown to be neuroprotective with memory enhancing
activity in the ischemic model [14], the APP-increasing effect of
baicalein may surpass its memory enhancing activity in AD
models. We consider that our study determines for the first time
that baicalein can potentiate Ab not only in a cell culture model
but also in an animal model of AD. These findings can contribute
to the design of further studies to assess whether treatment with
HLJDT or HLJDT-M may have an influence on AD.
Conclusions
In summary, these data provide convincing evidence for the first
time that treatment with HLJDT or its components RS or
baicalein can increase amyloidogenic processing of APP in a cell
model of AD. In addition, chronic baicalein administration to
TgCRND8 mice contributes to robustly increased plaque burden.
Thus, chronic treatment with baicalein or RS or HLJDT may
have deleterious effects in AD patients. However HLJDT-M
(HLJDT without RS) may be suitable for AD therapy because of
the presence of berberine and other protoberberine alkaloids,
which may act synergistically to reduce Ab production in AD
patients.
Supporting Information
Figure S1 Typical base peak chromatogram (A) and
extracted ion chromatograms (B) of HLJDT extracts. 1.
Geniposide; 2. Phellodendrine; 3. Columbamine; 4. Coptisine; 5.
Epiberberine; 6. Jatrorrhizine; 7. Baicalin; 8. Palmatine; 9.
Berberine; 10. Wogonoside; 11. Baicalein; and 12.Wogonin.
Identity of peaks 1, 4, 6, 7, 8, 9, 11, and 12 were ascertained
according to their m/z and retention time (Rt) when compared to
8 mixture reference solutions from the positive ion mode. The
peaks 2, 3, 5, and 10 were identified based on published articles
[21,22] related to the profiling of chemical components from all
the herbal components of HLJDT.
(TIF)
Table S1 The contents (%) of geniposide, berberine,
palmatine, baicalin, baicalein and wogonin in each
herbal extract of HLJDT quantified by HPLC analysis.
(DOCX)
Table S2 The analytical condition of LC-MS for the
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